Early stage and long term treatment of multiple sclerosis with interferon-β

Biologics: Targets and Therapy

Volumn 3, Issue , 2009, Pages 257-271

  Applebee, Angela ^a   Panitch, Hillel ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical trials; Interferon ; Multiple sclerosis; Neutralizing antibodies

Indexed keywords

EID: 84859426653     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S1473     Document Type: Review

References (79)

1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46:907-911.
2. Fisniku LK, Brex PA, Altmann DR et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset multiple sclerosis. Brain. 2008;131:808-817.
3. Bar-Or A, Oliviera EML, Anderson DE, et al. Molecular pathogenesis of multiple sclerosis. J Neuroimmunol. 1999;100:252-259.
4. Conlon P, Oksenberg JR, Zhang J. The immunobiology of multiple sclerosis: an autoimmune disease of the central nervous system. Neurobiol Dis. 1999;6:149-166.
5. Martin R, Stürzebecher CS, McFarland HF. Immunotherapy of multiple sclerosis: Where are we? Where should we go? Nature Immunol. 2001;2:785-788.
6. Yong VW, Chabot S, Stüve O, et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 1998;51:692-689.
7. Noronha A, Toscas A, Jensen MA. Interferon ββdecreases T-cell activation and interferon γγproduction in multiple sclerosis. J Neuroimmunol. 1993;46:145-154.
8. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology. 2002;58:S3-S9.
9. Graber JJ, Ford D, Zhan M, et al. Cytokine changes during interferonbeta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J Neuroimmunol. 2007;185:168-174.
10. Stüve O, Dooley NP, Uhm JH, et al. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol. 1996;40:853-863.
11. Leppert D, Waubant E, Bürk MR, et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol. 1996;40:846-852.
12. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-ββon blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol. 1995;37:611-619.
13. Kraus J, Ling AK, Hamm S, et al. Interferon-ββstabilizes barrier characteristics for brain endothelial cells in vitro. Ann Neurol. 2004;56:192-205.
14. Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol. 1997;41: 669-674.
15. Graber J, Zhan M, Ford D, et al. Interferonβ-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J Neuroimmunol. 2005;161:169-176.
16. Yong VW. Differential mechanisms of action of interferon-ββand glatiramer acetate in MS. Neurology. 2002;59:802-808.
17. Sharief MK, Semra YK, Seidi OA, et al. Interferon-beta therapy down regulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis. J Neuroimmunol. 2001;121:102-110.
18. Hamamcioglu K, Reder AT. Interferon-ββregulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler. 2007;13:459-470.
19. Biernacki K, Antel AP, Blain M et al. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol. 2005;62:563-568.
20. Byskosh PV, Reder AT. Interferon-ββeffects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler. 1996;1:262-269.
21. Reder AT, Veichko S, Yanaguchi KD, et al. IFNβ-1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res. 2008;28:317-331.
22. Stürzebecher S, Wandinger KP, Rosenwald A, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-ββin multiple sclerosis. Brain. 2003;126:1419-1429.
23. Yamaguchi KD, Ruderman DL, Croze E, et al. IFN-β-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. J Neuroimmunol. 2008;195:116-120.
24. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS council for Clinical Practice Guidelines. Neurology. 2002;58:169-178.
25. Knobler RL, Greenstein JL, Johnson KP, et al. Systemic recombinant human interferon-ββtreatment of relapsing-remitting multiple sclerosis: Pilot study analysis and six-year follow up. J Interferon Res. 1993;13:333-340.
26. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:662-667.
27. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33: 1444-1452.
28. Paty DW, Li DKB, UBC MS/MRI Study Group, et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multi-center, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:662-667.
29. IFNB Multiple Sclerosis Study Group; University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology. 1996;45:1277-1285.
30. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicenter randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352:1491-1497.
31. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS. Neurology. 2004;63:1788-1795.
32. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS. A combined analysis of the two trials. Neurology. 2004;63:1779-1787.
33. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta 1-b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006a;67:1242-1249.
34. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
35. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50: 121-127.
36. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3 year follow-up analysis of the BENEFIT study. Lancet. 2007;370:389-397.
37. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta 1-a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39:285-294.
38. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology. 1997;49:358-363.
39. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis. Ann Neurol. 2000;48:885-892.
40. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002;59: 1412-1420.
41. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology. 2002;59:1507-1517.
42. Clanet M, Kappos L, Hartung HP, et al. Interferon β-1a in relapsing multiple sclerosis: four-year extension of the European IFNβ-1a dosecomparison study. Mult Scler. 2004;10:139-144.
43. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59:679-687.
44. Fischer JS, Rudick RA, Cutter GR, et al. The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler. 1999;5:244-250.
45. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343:898-904.
46. Leary SM, Miller DH, Stevenson VL, et al. Interferon β-1a in primary progressive MS. An exploratory, randomized, controlled trial. Neurology. 2003;60:44-51.
47. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352: 1498-1504.
48. Li DKB, Paty DW, UBC MS/MRI Analysis Research Group and PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing remitting multiple sclerosis. Ann Neurol. 1999;46: 197-206.
49. PRISMS Study Group; University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS. Neurology. 2001;56:1628-1636.
50. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing remitting MS. Neurology. 2006b;67:944-953.
51. Once Weekly Interferon for MS Study Group (OWIMS). Evidence of interferon β-1a dose response in relapsing-remitting MS. Neurology. 1999;53:679-686.
52. Secondary Progressive Efficacy Clinical Trial of Recombinant 1-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Clinical Results. Neurology. 2001;56:1496-1504.
53. Li DKB, Zhao GJ, Paty DW, et al. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Neurology. 2001;56:1505-1513.
54. Comi F, Fillipi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized trial. Lancet. 2001;357:1576-1582.
55. Eillipi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomized, double-blind, placebo controlled trial. Lancet. 2004;364:1489-1496.
56. Durelli L, Verdun E, Barbero P, et al. Every other day interferon beta-1b vs once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicenter study (INCOMIN). Lancet. 2002;359:1453-1460.
57. Panitch HS, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β1-a treatment regimens in MS: the EVIDENCE Trial. Neurology. 2002;59:1496-1506.
58. Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, highfrequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial. J Neurol Sci. 2005;239:67-74.
59. Schwid SR, Thorpe J, Sharief M, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the evidence study. Arch Neurol. 2005;62:785-792.
60. Koch-Henriksen N, Sørensen PS, Christensen T, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology. 2006;66:1056-1060.
61. Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology. 1999;53: 1622-1627.
62. Lublin FD, Whitaker JN, Eidelman BH, et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 1996;46:12-18.
63. Munschauer FE, Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther. 1997;19:883-893.
64. Baum K, O'Leary C, Ferrer FC, et al. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b. Mult Scler. 2007;13:1153-1160.
65. Kümpfel T, Schwan M, Pollmächer T, et al. Time of interferon-β-1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients. Mult Scler. 2007;13:1138-1145.
66. Rice GP, Ebers GC, Lublin FD, et al. Ibuprofen treatment versus gradual introduction of interferon β1-b in patients with MS. Neurology. 1999;52:1893-1895.
67. Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the β-interferons for MS: a comparison between three products. Neurology. 2004;62:628-631.
68. Francis GS, Grumser Y, Alteri E, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-β-1a: incidence and clinical significance. Drug Safety. 2003;26:815-827.
69. Yoshida EM, Rasmussen SL, Steinbrecher UP, et al. Fulminant liver failure during interferon-beta treatment of multiple sclerosis. Neurology. 2001;56:1416.
70. Perini P, Calabrese M, Biasi G, et al. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol. 2004;251:305-309.
71. Rice GP, Paszner B, Oger J, et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b. Neurology. 1999;52:1277-1279.
72. Rice G. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Arch Neurol. 2001;58:1297-1298.
73. Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology. 1998;51:1698-1702.
74. Giovannoni G, Barbarash OL, Jaber A, et al. Reduced immunogenicity with a new formulation of interferon of interferon-beta-1a (Rebif ®): 24-week results of a phase IIIb study. Mult Scler. 2006; 12(Suppl 1):S192.
75. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007;68:977-984.
76. Boskovic R, Wide R, Wolpin J, et al. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology. 2005;65:807-811.
77. Patti F, Russo P, Pappalardo A, et al. Predictors of quality of life among patients with multiple sclerosis: an Italian cross-sectional study. J Neurol Sci. 2007;252:121-129.
78. Bayer Schering Pharma AG. BEYOND study: results do not support regulatory filing for Betaferon®500 μg. Press Release. Leverkusen, Germany: Bayer Schering Pharma AG; 2007.
79. Lublin FD, Reingold SC, National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Placebocontrolled clinical trials in multiple sclerosis: ethical considerations. Ann Neurol. 2001;49:677-681.